Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off the shelf natural killer (NK) cell therapies for cancer.

Sector

Manufacturing

Industry

Pharmaceutical Preparation Manufacturing

www.nkartatx.com →

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Alerts

News

What to Know About Tesla's Terafab Project and the Company's AI Future

Tantalus Systems Holding Inc. (GRID:CA) Q4 2025 Earnings Call Transcript

LetPot Achieves Amazon Best Seller Status Across Multiple Markets in 2025 Holiday Season

TITAN S A (TTCIF) Q4 2025 Earnings Call Transcript

Forerunner Ventures Builds $227 Million Position in Chime Financial, According to Recent SEC Filing

Micron Has Soared in 2026 as Its Profit Skyrockets: Is It Too Late to Buy?

This Nuclear Dividend Stock Could Turn $1,000 Into a Lifetime Income Stream

Toast: Focus On ARR Growth And EBITDA Expansion

Firefly Aerospace Inc. (FLY) Q4 2025 Earnings Call Transcript

FedEx Corporation (FDX) Q3 2026 Earnings Call Transcript

Flowco Holdings Inc. Announces Pricing of Public Offering by Selling Stockholders

WePlay Launches Charity Initiative in Indonesia: Bringing Warmth and Hope to Children at a Jakarta Orphanage

WePlay Gelar Aksi Sosial di Indonesia, Hadirkan Harapan bagi Anak Panti Asuhan di Jakarta

FLEX LNG: Iran Conflict Boosts Rates, But Risks Are Rising Fast

Why Poet Technologies Stock Was Sliding This Week

CPaaS Platform uSpeedo Enables Global SMS and Email for AI Agents via OpenClaw Skills

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Corcept Therapeutics Incorporated to Secure Counsel Before Important Deadline in Securities Class Action - CORT

Samsonite Group S.A. (SMSEY) Q4 2025 Earnings Call Transcript

NIHI: Tax-Efficient Way To Collect A 10% Yield From International Stocks

Lands' End: A Return To Growth In Q4, Shares Fairly Valued

About